DYNE THERAPEUTICS INC
DYNNASDAQ🏆 #1592 by market capEarnings Oct 29US Equity
$17.02▲ $0.05 (+0.29%)
After hours · at closeTrack DYN
Get earnings, price moves & breaking news on Telegram
24h▲ 0.3%
7d▲ 7.9%
14d▲ 11.3%
30d▲ 4.9%
ytd▼ 13.0%
1y▼ 28.0%
🏦Market Cap
$3.18B
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
40
Weak
Trading Snapshot
- Day Range
- $16.75 – $17.59
- 52-Week Range
- $14.00 – $27.31
- Volume (shares)
- 120,260
- Avg Volume (shares)
- —
- Shares Outstanding
- 186.7M
- Next Earnings
- 2026-10-29
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -5.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-3.14
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +25.9%
DYNE THERAPEUTICS INC
DYNFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$468M▲ +36.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$405M▲ +37.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
128.4M▲ +25.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$873M▲ +$462M YoY
StockOtter · stockotter.spaceAbout DYNE THERAPEUTICS INC
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
40/100
Analyst data unavailable.
Latest News & Updates
News unavailable.